Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
January 09, 2022 12:00 ET
|
Exagen Inc.
SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a...
Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 17, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33rd Annual Virtual...
Exagen Inc. Reports Third Quarter 2021 Results
November 10, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021....
Exagen Inc. to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum
November 04, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity Virtual...
Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021
October 27, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021...
Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus
October 27, 2021 08:25 ET
|
Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered...
Exagen Inc. Announces $27.2 Million Debt Refinancing
October 25, 2021 08:25 ET
|
Exagen Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security...
Exagen Showcases Eight Scientific Presentations at ACR’s Virtual Annual Meeting in November 2021
October 21, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the...
Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 13, 2021 16:15 ET
|
Exagen Inc.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global...
Exagen Inc. Reports Second Quarter 2021 Results
August 09, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2021. ...